Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Core Insights - Capricor Therapeutics shares are experiencing significant upward momentum due to recent positive developments regarding its therapy Deramiocel [1][4]. Group 1: FDA Approval and Clinical Trials - The FDA has lifted a Complete Response Letter issued in July 2025 after Capricor resubmitted data from its HOPE-3 Phase 3 trial, which was classified as a Class 2 resubmission [2]. - Deramiocel demonstrated positive results in the HOPE-3 trial, achieving the primary endpoint and all Type I error-controlled secondary endpoints [2][3]. - The therapy has the potential to be the first treatment addressing both skeletal and cardiac complications of Duchenne muscular dystrophy, a rare genetic disorder [3]. Group 2: Stock Performance - Capricor Therapeutics shares rose from a 52-week low of $4.60 in early December 2025 to approximately $35.80 by early March 2026, indicating a strong rally [4]. - The stock is trading significantly above its 20-day, 50-day, and 200-day moving averages, suggesting a bullish trend and strong investor interest [4]. - On a recent Tuesday morning, CAPR shares were up 17.21% at $35.90, reflecting ongoing positive market sentiment [6]. Group 3: Market Sentiment and Rankings - Benzinga's Edge Rankings indicate that Momentum is the strongest category for CAPR, scoring 98.75 out of 100 [5].